인디애나의 난소암 임상 시험
난소암 관련 연구 23개가 인디애나 내 여러 지역에서 참여자를 모집하고 있습니다.
인디애나의 도시
공식 연구 텍스트(영어)
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0284 - Community Cancer Center North, Indianapolis
- Site 0217 - St Vincent Hospital and Health Care Centers, Indianapolis
피험자 모집 중2상
18세 이상 · 여성 · 2026. 9. 29. 업데이트됨 · NCT05128825Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- UChicago Medicine Northwest Indiana, Crown Point
- Woodland Cancer Care Center, Michigan City
피험자 모집 중2상
전 연령 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT05564377A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Parkview Research Center /ID# 274338, Fort Wayne
- Indiana University Melvin and Bren Simon Cancer Center /ID# 275492, Indianapolis
피험자 모집 중2상
18세 이상 · 여성 · 2026. 9. 29. 업데이트됨 · NCT06890338Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Community Health Network, Indianapolis
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06128551A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Indiana University (IU) School of Medicine, Indianapolis
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07213791A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health, Indianapolis
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07213804A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Parkview Research Center at Parkview Regional Medical Center ( Site 0055), Fort Wayne
- Franciscan Health Indianapolis ( Site 0081), Indianapolis
피험자 모집 중3상
18세 이상 · 여성 · 2026. 9. 17. 업데이트됨 · NCT07318558A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Parkview Research Center, Fort Wayne
피험자 모집 중2상
18세 ~ 99세 · 여성 · 2026. 9. 15. 업데이트됨 · NCT07023627A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- IU Simon Cancer Center, Indianapolis
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT06465069A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Parkview Research Center at Parkview Regional Medical Center ( Site 0003), Fort Wayne
피험자 모집 중3상
18세 이상 · 여성 · 2026. 9. 3. 업데이트됨 · NCT06824467Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
피험자 모집 중3상
18세 이상 · 여성 · 2026. 8. 26. 업데이트됨 · NCT05281471Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
피험자 모집 중1상
15세 이상 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Riley Hospital for Children, Indianapolis
피험자 모집 중1/2상
12 Months – 30 Years · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT04851119A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
- Indiana University, Indianapolis
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 21. 업데이트됨 · NCT07306559A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- IU Health North Hospital, Carmel
- UChicago Medicine Northwest Indiana, Crown Point
- Goshen Center for Cancer Care, Goshen
- 외 2개
피험자 모집 중
35세 ~ 50세 · 여성 · 2026. 8. 7. 업데이트됨 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- IU Health North Hospital, Carmel
- Northwest Cancer Center - Crown Point, Crown Point
- UChicago Medicine Northwest Indiana, Crown Point
- 외 13개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 7. 업데이트됨 · NCT06580314A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Community Health Network, Indianapolis
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 7. 30. 업데이트됨 · NCT04657068A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Community Health Network - MD Anderson, Indianapolis
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 7. 28. 업데이트됨 · NCT06161025A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- UChicago Medicine - Northwest Indiana, Crown Point
- Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne
- Community Health Network, Inc, Indianapolis
- 외 3개
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT04389632Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Indiana University, Indianapolis
피험자 모집 중3상
18세 이상 · 여성 · 2026. 7. 2. 업데이트됨 · NCT06819007Integrated Cancer Repository for Cancer Research
- Parkview Research Center, Fort Wayne
피험자 모집 중관찰 연구건강한 지원자 환영
19세 ~ 110세 · 모든 성별 · 2026. 6. 29. 업데이트됨 · NCT02012699Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 4. 1. 업데이트됨 · NCT05735080cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Floyd, New Albany
피험자 모집 중관찰 연구건강한 지원자 환영
40세 이상 · 모든 성별 · 2026. 1. 20. 업데이트됨 · NCT05366881ClinicalTrials.gov 출처, 2026. 10. 1. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.